PP_1170x120_10-25-21

Xeloda

Aurobindo receives FDA approval for capecitabine tablets

Aurobindo receives FDA approval for capecitabine tablets

EAST WINDSOR, N.J. — Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for capecitabine tablets USP, 150 mg, and 500 mg. Aurobindo’s capecitabine tablets USP are an AB-rated generic equivalent to the reference listed drug Xeloda. Capecitabine tablets are indicated for the treatment of

Adheris Health